Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Hyperhidrosis - Management
Additional information

Treatments in secondary care

  • Modified topical therapy:
    • Emollients, topical corticosteroids, different strengths of aluminium salts (up to 50%), and topical glutaraldehyde or formaldehyde may be used.
    • Topical glycopyrrolate (an antimuscarinic agent) can be prepared by special order manufacturers, and may be useful for primary craniofacial hyperhidrosis.
  • Iontophoresis:
    • In tap water iontophoresis, the sites of hyperhidrosis are immersed in warm water (or a wet contact pad may be applied) through which a weak electric current is passed.
    • If unsuccessful, glycopyrronium bromide (an antimuscarinic agent) can be added to the water, but adverse effects are common.
    • It is usually performed in hospital, but home treatment kits (using tap water) can be purchased for £250 to £500.
    • Treatment usually consists of 2–4 treatment sessions per week. Each treatment session lasts 20–30 minutes. Improvement usually occurs after 4–10 sessions.
    • Maintenance treatment is typically required at intervals of 1–4 weeks.
    • No serious adverse effects are reported for tap water iontophoresis, but it is only suitable for the hands, feet and, less easily, the axillae.
  • Botulinum toxin:
    • Botulinum toxin is delivered by multiple intradermal injections to the affected areas.
    • Botox® is licensed for the treatment of axillary hyperhidrosis; botulinum toxin can also be helpful for palmar, plantar, and craniofacial hyperhidrosis but the procedure may be more difficult and painful at these sites.
    • Adverse effects include compensatory sweating (5–10%) and injection-site pain or reactions (9–12%). Transient muscle weakness and loss of fine motor control, as well as anaphylaxis, have been reported, and transmission of infectious agents is theoretically possible.
    • It is not always available at NHS hospitals, and is mostly given in private clinics.
  • Surgery:
    • Resection of sweat glands can be carried out using local anaesthesia and is useful for small areas of axillary hyperhidrosis.
    • Endoscopic thoracic sympathectomy (ETS):
      • This involves video-assisted laparoscopic division of the sympathetic chain over the neck of the ribs under general anaesthesia, usually by a vascular surgeon.
      • ETS is indicated (as a last resort) for severe palmar, axillary, and sometimes craniofacial hyperhidrosis. Lumbar sympathectomy is not used for plantar hyperhidrosis because of the risk of sexual dysfunction.
      • Complications include: compensatory hyperhidrosis (very common, up to 100%), gustatory sweating (common, up to 50%), rhinitis (quite common, up to 10%), pneumothorax (common, up to 75%, but usually resolves spontaneously), significant bleeding (up to 5%), Horner's syndrome (rare, < 1%), and phrenic nerve damage (extremely rare).
  • Other treatments that may be used:
    • Oral antimuscarinics, such as glycopyrronium bromide (which needs to be imported) and oxybutinin, may be used, but their use is limited by adverse effects.
    • Clonidine.
    • Diltiazem.
    • Benzodiazepines.

© NHS Institute for Innovation and Improvement